Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Smart Immune ProTcell: first-in-class allogeneic thymus empowered T cell therapy platform for fast and durable immune system reconstitution

Objective

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is used in immunodeficiencies & blood malignancies though costly, hard-to-access & linked to many severe complications. Smart Immune puts forth a high-profile solution to solve this gap: ProTcell platform supplies clinical-grade, allogeneic lymphoid progenitor cells produced in just 7 days ex-vivo. These are made into tolerant polyclonal mature T cells by the patients own thymus in a record <3 months (vs. 15-24 months naturally), & reducing complications since infused in our 1st patient (June 2020). With strong IP, orphan drug label secured & traction across eminent KOLs in >7 countries, we face a window opportunity. With the EICs support, we pursue the less attractive-to-VCs SCID indication, as part of our Series A, to become a front row T-cell therapy player, with future chimeric antigen receptor (CAR) therapies in mind. We project to treat >40k patients by 2030 & recover a ROI of 5,28 over our target Series A.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

SMART IMMUNE
Net EU contribution
€ 2 495 937,50
Address
67 RUE DE SEINE
75006 Paris
France
SME
Yes
Region
Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 565 625,00